News

Fierce Pharma7d
Apellis counters Novartis with broad label for Empaveli in kidney disease
Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...
Apellis wins FDA label expansion for Empaveli in rare kidney disorders
Apellis Pharmaceuticals (NASDAQ:APLS) announced on Tuesday that the U.S. FDA approved its injectable medication Empaveli for ...